SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Vapendavir-d_5

Item No. 31320

CAS Registry No.:	2738376-73-1
Formal Name:	3-(ethoxy-d_5)-6-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-1,2-benzisoxazole
Synonym:	BTA798-d_5
MF:	$C_{21}H_{21}D_5N_4O_3$
FW:	387.5
Chemical Purity:	≥98% (Vapendavir)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_5); ≤1% d_0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vapendavir-d_5 is intended for use as an internal standard for the quantification of vapendavir (Item No. 30546) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Vapendavir-d_5 is supplied as a solid. A stock solution may be made by dissolving the vapendavir-d_5 in the solvent of choice, which should be purged with an inert gas. Vapendavir-d_5 is soluble in DMSO and methanol.

Description

Vapendavir is a capsid-binding antiviral agent.[1,2] It binds to a pocket in the human rhinovirus (HRV) strain HRV2 VP1 capsid protein and inhibits the cytopathic effects of HRV2 and HRV14 in HeLa Ohio cells (EC_{50}s = 1 and 5 ng/ml, respectively), as well as in a panel of 39 HRV clinical isolates (median EC_{50} = 7.3 ng/ml).[1] Vapendavir inhibits replication in a panel of 21 enterovirus 71 (EV71) isolates with an average EC_{50} value of 0.7 µM.[2]

References

1. Feil, S.C., Hamilton, S., Krippner, G.Y., *et al*. An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. *ACS Med. Chem. Lett.* **3(4)**, 303-307 (2012).
2. Tijsma, A., Franco, D., Tucker, S., *et al*. The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. *Antimicrob. Agents Chemother.* **58(11)**, 6990-6992 (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM